Skip to main content
Premium Trial:

Request an Annual Quote

Stratagene Shares Down 6 Percent on Q2 Loss

NEW YORK (GenomeWeb News) - Shares in Stratagene were down approximately 6 percent, or $.43, at $6.41 in mid-afternoon trading today after the company said that litigation-related charges swung second-quarter earnings to a loss.
 
As GenomeWeb News reported this morning, Stratagene said total revenues were down 6 percent to $23.4 million due to poor sales of its gene-discovery and cloning systems products.
 
The company’s net loss of $3.7 million reflects the litigation charges from the patent case involving Invitrogen's patents.
The Scan

Gone, But Now Reconstructed SARS-CoV-2 Genomes

In a preprint, a researcher describes his recovery of viral sequences that had been removed from a common database.

Rare Heart Inflammation Warning

The Food and Drug Administration is adding a warning about links between a rare inflammatory heart condition and two SARS-CoV-2 vaccines, Reuters reports.

Sandwich Sampling

The New York Times sent tuna sandwiches for PCR analysis.

Nature Papers Describe Gut Viruses, New Format for Storing Quantitative Genomic Data, More

In Nature this week: catalog of DNA viruses of the human gut microbiome, new dense depth data dump format to store quantitative genomic data, and more.